Advanced Biomed Inc.
Health Care · Biotechnology
Liquid biopsy / CTC detection is an emerging and high-value segment of precision oncology diagnostics; ADVB holds a proprietary microfluidic platform spanning enrichment through single-cell analysis, covering the full CTC workflow. 6M shares outstanding.
ADVB is a pre-revenue development-stage company with accumulated deficits exceeding $19M. It faces entrenched competition from Foundation Medicine, Guardant Health, and others with far greater capital and clinical evidence bases. 6M shares, very low daily volume) makes the stock highly illiquid and susceptible to extreme volatility.
No product has received full commercial approval as of mid-2026.
No major news in the last 7 days for ADVB - only listicles and opinion pieces, which we filter out by default. See everything anyway.
No key levels recorded for this ticker.